• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高纤维母细胞激活蛋白表达在去势抵抗性前列腺癌中支持 FAPI-分子治疗学的应用。

High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.

机构信息

Department of Urology, University of Duisburg-Essen, and German Cancer Consortium (DKTK), University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

出版信息

Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):385-389. doi: 10.1007/s00259-021-05423-y. Epub 2021 Jul 5.

DOI:10.1007/s00259-021-05423-y
PMID:34226953
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8712308/
Abstract

PURPOSE

To evaluate fibroblast-activation-protein (FAP) expression in different clinical stages of prostate cancer (PC) with regards to utility of [ Ga]Ga-FAPI-04 PET/CT imaging in patients with castration-resistant PC (CRPC).

METHODS

Tissue microarrays (TMAs) were constructed from prostatic tissue from 94 patients at different stages of PC (primary PC, patients undergoing neoadjuvant androgen deprivation therapy, CRPC, and neuroendocrine PC (NEPC)) and were stained with anti-FAP monoclonal antibody. A positive pixel count algorithm (H-Index) was used to compare FAP expression between the groups. Additionally, three men with advanced CRPC or NEPC underwent [ Ga]Ga-FAPI-04 PET/CT, and PET positivity was analyzed.

RESULTS

The mean H-index for benign tissue, primary PC, neoadjuvant androgen deprivation therapy before radical prostatectomy, CRPC, and NEPC was 0.018, 0.031, 0.042, 0.076, and 0.051, respectively, indicating a significant rise in FAP expression with advancement of disease. Corroborating these findings [ Ga]Ga-FAPI-04 PET/CT was highly positive in men with advanced CRPC.

CONCLUSION

Increased FAP tissue expression supports the use of FAP inhibitor (FAPI)-molecular theranostics in CRPC.

摘要

目的

评估成纤维细胞激活蛋白(FAP)在前列腺癌(PC)不同临床阶段的表达情况,探讨其在去势抵抗性前列腺癌(CRPC)患者中的[Ga]Ga-FAPI-04 PET/CT 成像的应用价值。

方法

从 94 例处于不同 PC 阶段(原发性 PC、接受新辅助雄激素剥夺治疗的患者、CRPC 和神经内分泌 PC(NEPC))的前列腺组织中构建组织微阵列(TMA),并用抗 FAP 单克隆抗体进行染色。采用阳性像素计数算法(H-指数)比较各组之间 FAP 表达。此外,对 3 例晚期 CRPC 或 NEPC 男性进行[Ga]Ga-FAPI-04 PET/CT 检查,分析 PET 阳性情况。

结果

良性组织、原发性 PC、根治性前列腺切除术前新辅助雄激素剥夺治疗、CRPC 和 NEPC 的平均 H-指数分别为 0.018、0.031、0.042、0.076 和 0.051,表明随着疾病的进展 FAP 表达显著增加。这些发现与[Ga]Ga-FAPI-04 PET/CT 的结果一致,在晚期 CRPC 男性中具有高度阳性。

结论

FAP 组织表达增加支持在 CRPC 中使用 FAP 抑制剂(FAPI)分子治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30ee/8712308/9ae662aa9560/259_2021_5423_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30ee/8712308/c712b3a186ca/259_2021_5423_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30ee/8712308/9ae662aa9560/259_2021_5423_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30ee/8712308/c712b3a186ca/259_2021_5423_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30ee/8712308/9ae662aa9560/259_2021_5423_Fig2_HTML.jpg

相似文献

1
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.高纤维母细胞激活蛋白表达在去势抵抗性前列腺癌中支持 FAPI-分子治疗学的应用。
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):385-389. doi: 10.1007/s00259-021-05423-y. Epub 2021 Jul 5.
2
Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression.镓 FAPI-04 PET/CT 在非小细胞肺癌中的应用:准确评估淋巴结转移及与成纤维细胞激活蛋白表达的相关性。
J Nucl Med. 2024 Apr 1;65(4):527-532. doi: 10.2967/jnumed.123.266806.
3
PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using Ga-FAP-2286: Comparison with F-FDG and Ga-FAPI-46 in a Single-Center, Prospective Study.使用 Ga-FAP-2286 对多种癌症中的成纤维细胞激活蛋白进行 PET 成像:在单中心前瞻性研究中与 F-FDG 和 Ga-FAPI-46 的比较。
J Nucl Med. 2023 Mar;64(3):386-394. doi: 10.2967/jnumed.122.264544. Epub 2022 Sep 2.
4
Correlation of Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study.Ga-FAPi-46 PET 生物分布与免疫组化检测实体瘤患者 FAP 表达的相关性:一项前瞻性转化性探索性研究的中期分析。
J Nucl Med. 2022 Jul;63(7):1021-1026. doi: 10.2967/jnumed.121.262426. Epub 2021 Nov 5.
5
Ga-Labeled Fibroblast Activation Protein Inhibitor (Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the Ga-FAPI PET Observational Trial.Ga 标记成纤维细胞激活蛋白抑制剂 (Ga-FAPI) PET 用于胰腺导管腺癌:Ga-FAPI PET 观察性试验的数据。
J Nucl Med. 2023 Dec 1;64(12):1910-1917. doi: 10.2967/jnumed.122.264827.
6
Detecting Fibroblast Activation Proteins in Lymphoma Using Ga-FAPI PET/CT.利用 Ga-FAPI PET/CT 检测淋巴瘤中的成纤维细胞激活蛋白。
J Nucl Med. 2022 Feb;63(2):212-217. doi: 10.2967/jnumed.121.262134. Epub 2021 May 28.
7
A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.一种放射性核素标记的荧光素-18 和镥-177 纤维母细胞激活蛋白靶向治疗的放射性诊断与治疗配体。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2331-2341. doi: 10.1007/s00259-023-06169-5. Epub 2023 Mar 3.
8
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
9
Impact of Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas.Ga-FAPI PET/CT 成像对原发性和复发性胰腺导管腺癌治疗管理的影响。
J Nucl Med. 2021 Jun 1;62(6):779-786. doi: 10.2967/jnumed.120.253062. Epub 2020 Oct 23.
10
Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04.利用 Ga 标记的成纤维细胞激活蛋白抑制剂 FAPI-04 对心肌梗死后成纤维细胞活性进行分子成像。
J Nucl Med. 2019 Dec;60(12):1743-1749. doi: 10.2967/jnumed.119.226993. Epub 2019 Aug 12.

引用本文的文献

1
Multitracer comparison of gold standard PSMA-PET/CT with Ga-FAPI and F-FDG in high-risk prostate cancer: a proof-of-concept study.金标准PSMA-PET/CT与镓标记的成纤维细胞激活蛋白抑制剂(Ga-FAPI)及氟代脱氧葡萄糖(F-FDG)在高危前列腺癌中的多示踪剂比较:一项概念验证研究
Eur J Nucl Med Mol Imaging. 2025 May 27. doi: 10.1007/s00259-025-07352-6.
2
Dual targeting PET tracer [Ga]Ga-PSFA-01 in patients with prostate cancers: A pilot exploratory study.双靶点正电子发射断层显像示踪剂[镓]Ga-PSFA-01在前列腺癌患者中的初步探索性研究。
Theranostics. 2025 Mar 10;15(9):4124-4134. doi: 10.7150/thno.108676. eCollection 2025.
3
The role of cancer-associated fibroblasts in the tumour microenvironment of urinary system.
癌症相关成纤维细胞在泌尿系统肿瘤微环境中的作用。
Clin Transl Med. 2025 Apr;15(4):e70299. doi: 10.1002/ctm2.70299.
4
Design, preclinical evaluation, and first-in-human PET study of [Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer.[镓]Ga-PSFA-01的设计、临床前评估及首次人体PET研究:一种PSMA/FAP异二价示踪剂
Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):1166-1176. doi: 10.1007/s00259-024-06965-7. Epub 2024 Nov 9.
5
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.去势抵抗性前列腺癌中免疫组织化学和PET成像检测FAP和PSMA表达:一项转化性初步研究
J Nucl Med. 2024 Dec 3;65(12):1952-1958. doi: 10.2967/jnumed.124.268037.
6
Is There a Role for FAPI PET in Urological Cancers?FAPI PET 在泌尿系统癌症中的作用如何?
Mol Diagn Ther. 2024 Nov;28(6):721-725. doi: 10.1007/s40291-024-00735-9. Epub 2024 Aug 24.
7
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.前列腺癌中前列腺特异性膜抗原(PSMA)表达、调控及异质性的生物学决定因素
Nat Rev Urol. 2025 Jan;22(1):26-45. doi: 10.1038/s41585-024-00900-z. Epub 2024 Jul 8.
8
The diagnostic value of [F]FAPI-42 PET/CT for pulmonary artery masses: comparison with [F]FDG PET/CT.[F]FAPI-42 PET/CT 对肺动脉肿块的诊断价值:与[F]FDG PET/CT 的比较。
Eur Radiol. 2024 Nov;34(11):7233-7243. doi: 10.1007/s00330-024-10821-5. Epub 2024 Jun 4.
9
From biology to the clinic - exploring liver metastasis in prostate cancer.从生物学到临床 - 探索前列腺癌中的肝转移。
Nat Rev Urol. 2024 Oct;21(10):593-614. doi: 10.1038/s41585-024-00875-x. Epub 2024 Apr 26.
10
Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer.分子成像揭示肿瘤细胞和肿瘤基质的异质性进展:18F-氟代脱氧葡萄糖正电子发射断层显像(FDG PET)和纤维母细胞激活蛋白抑制剂正电子发射断层显像(FAPI PET)在诊断进展期前列腺癌PSMA阴性骨转移中的应用
Am J Nucl Med Mol Imaging. 2024 Feb 20;14(1):13-21. doi: 10.62347/HVLF3619. eCollection 2024.